Medical affairs & evidence generation

• Medical strategyThe disease setting, the treatment pathway and the decisions that call for better evidence, framed as the questions treating physicians will ask.
• Evidence-gap analysisWhat is known and what is not: sequencing, subgroups, long-term safety, combinations and special populations.
• Evidence planPrioritized studies, including post-marketing commitments, investigator-initiated research, registries and real-world evidence, each tied to a question and a decision.
• Scientific communicationThe scientific narrative, publication and congress plan, and the design of advisory boards.
• TransitionThe hand-off from clinical development to medical affairs: ownership, timelines and what pivotal data collection should capture.

A registration program answers a defined question. Clinical practice then raises many more, and without an explicit plan evidence generation turns into a long list of requests from every direction.

Planning before approval is the cheapest moment to align what pivotal trials collect with what you will later need to say.

• Ahead of an anticipated filing or approval,when medical planning begins.
• At a new indication or lifecycle milestone
• When study requests competefor the same budget and attention.
• When building a first medical-affairs function,or moving from development into medical strategy.

1. Define the questions From the literature, congress discussion and, within compliance limits, clinician input.
2. Prioritize Weigh each gap by its effect on practice, its feasibility and its cost.
3. Design Study concepts and real-world evidence feasibility, developed with epidemiology and biostatistics specialists.
4. Communicate A scientific narrative, publication plan and communication priorities consistent with the evidence.

• A structured medical and evidence-gap assessment
• A prioritized evidence-generation roadmap
• Study concepts or research-question recommendations
• A scientific narrative and communication-priority framework

• StructureA medical-strategy review, an evidence-planning workshop, or a defined evidence and scientific-content project.
• What we need from youThe asset and indication context, current evidence, the development or medical plan, and the questions stakeholders are raising.
• Roles and limitsResearch design, data access and analysis are planned with epidemiology, biostatistics and operations specialists. External activities follow your medical, legal and regulatory review processes. We do not produce promotional material.